Relypsa Announces FDA Approval of Supplemental New Drug Application to Enable the Usage of Veltassa® (patiromer) With or Without Food
08 mai 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced that the United States (U.S) Food and Drug Administration (FDA) approved a...
Relypsa Presents Patiromer Clinical Trial Data on Serum Potassium in Patients with Hyperkalemia at the National Kidney Foundation 2018 Spring Clinical Meetings
11 avr. 2018 08h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Relypsa, Inc., a Vifor Pharma Group company, today announced results from a pooled analysis of three clinical trials evaluating the effects...
Relypsa Names Sylvia R. Wheeler V.P. Investor Relations and Corporate Affairs
02 avr. 2014 09h00 HE
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 2, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the appointment of Sylvia R. Wheeler to the position of Vice...